APAC demand for minimally invasive neurosurgery strengthens on new trial data

ICH and tumour-care devices gain traction as evidence and reimbursement improve.

New clinical evidence is accelerating adoption of minimally invasive neurosurgical techniques across Asia-Pacific (APAC), particularly for intracranial haemorrhage (ICH) and brain tumour interventions. 

GlobalData forecasts the global minimally invasive neurosurgical devices market to grow at a 6% CAGR from 2024 to 2034, with APAC among the fastest-growing regions. Growth is driven by rising ICH incidence, increased investment in neurosurgical capability, and early moves by payers to evaluate reimbursement for minimally invasive procedures.

Ultrasonic aspiration systems remain the most widely adopted minimally invasive technology. Their safety profile and broad clinical utility are reinforcing their use as hospitals trial newer options for ICH evacuation and tumour removal.

“Reimbursement remains a key consideration for market growth,” said Thomas Fleming, Medical Analyst at GlobalData. “Following favourable trial results, minimally invasive devices are expected to receive higher incidents of government reimbursement. Without this support, the cost of disposable components can limit adoption in cost-sensitive markets.”

Fleming added that continuous trial readouts will play a critical role in expanding clinical acceptance. “As evidence accumulates and reimbursement frameworks improve, minimally invasive neurosurgical devices are positioned for substantial growth,” he said.